Cell and gene therapy investment strategy pivots as funding dries up
Later-stage financing deals for cell and gene therapy companies reflects a broader derisking trend in the pharma industry.
Cytiva Navigating cell therapy WP 4
Solid Biosciences’ SGT-212 gains FDA rare paediatric disease status
Regeneron and Tessera join forces to forge in vivo AATD gene therapy
Potentially “groundbreaking” FDA gene therapy pathway leaves key issues unresolved
IASO Bio gains Hong Kong approval for Fucaso application
UK-developed leukaemia cell therapy to be offered on NHS
Aspen closes $115m in Series C to advance Parkinson’s cell therapy
USPTO grants patent to Genprex’s Reqorsa gene therapy
